RxDoctor Payments DataLook up a doctor →

David Lindley, DO

Interventional Pain Medicine · Mineral Wells, TXNPI 1245264621

Payments from drug & device makers

$60,392in general payments, 2019–2025

Across 542 payments — averaging $111.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Tersera Therapeutics LLC$42K
  • Medtronic$9K
  • Hydrocision, Inc.$8K
  • Pylant Medical$300
  • Arthrex$272
  • AbbVie$159
  • plus $353 from 11 others
$3,825in research payments, 2019–2025

Across 1 payment — averaging $3825.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Tersera Therapeutics LLC$4K

What the payments were for

  • Consulting fees$43,78973%
  • Speaking & faculty fees$3,5046%
  • Travel & lodging$2,3424%
  • Food & beverage$10,30917%
  • Education$4481%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$60,392 in reported general payments places this provider in the 90th percentile of 287 interventional pain medicine providers in Texas.

See all interventional pain medicine providers in Texas

Medicare billing

Part B allowed, 2024
$636,151
Medicare patients
468
Services billed
21,285

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide13$6,748
Gabapentin430$6,024
Tizanidine Hcl232$3,639
Celecoxib191$2,876
Pregabalin114$2,284
Baclofen70$1,435
Cyclobenzaprine Hcl107$1,352
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen30$1,030
Methocarbamol59$809
Oxycodone Hcl12$220
Hydroxyzine Hcl13$171
Cephalexin19$94
Meloxicam39$90
Hydromorphone Hcl12$83
Tramadol Hcl18$52

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$159$6,74813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 287 interventional pain medicine providers in Texas.

Other interventional pain medicine in Mineral Wells

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →